Insights
Search Results
Client Highlights
7.21.26
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch
On July 20, 2026, Freenome Holdings, Inc. (Freenome), an early cancer detection company developing blood-based screening tests, announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (PCSC). The combined company is renamed Freenome, Inc., and its common stock commenced trading on the Nasdaq Capital Market on July 21, 2026, under the new ticker symbol “FRNM.” Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Client Highlights
7.08.26
Wilson Sonsini Advises Crinetics on Patent Matters Related to $10 Billion Acquisition by Vertex
On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases, announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Wilson Sonsini Goodrich & Rosati is patent counsel to Crinetics and advised the company on patent matters related to the transaction.
Client Highlights
6.10.26
Wilson Sonsini Advises SonoThera on Patent Matters Related to Oversubscribed $125 Million Series B
On June 10, 2026, SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. Wilson Sonsini Goodrich & Rosati advised SonoThera on patent matters related to the transaction.
Alerts
6.08.26
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals
In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed drug), failed to plausibly allege that Hikma actively induced infringement of Amarin’s method of use patents based on Hikma’s statements and materials related to its generic version of Vascepa®, reversing the decision by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit). Although much of the import of this decision will not be fully understood until lower courts interpret this ruling, the Supreme Court provided guidance regarding one of the requirements for alleging a claim for induced patent infringement—one must plausibly allege that the defendant actively encouraged infringing use, not merely whether others could plausibly read statements by the defendant as instructions to infringe.
Client Highlights
6.05.26
Firm Advises Ona Therapeutics on IP Matters Related to $86.6 Million Series B
On June 4, 2026, Ona Therapeutics, a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, announced the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life Sciences, Asabys Partners, Bpifrance, as part of the InnoBio investment strategy, CDTI through SICC Innvierte, FundPlus NV, and Ysios Capital. Wilson Sonsini Goodrich & Rosati advised Ona Therapeutics on IP matters related to the transaction.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
Newsletters
6.03.26
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
6.02.26
Wilson Sonsini Advises BVF Partners on IP Matters Related to Contraline’s $92.5 Million Series B
On June 2, 2026, Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Wilson Sonsini Goodrich & Rosati advised BVF Partners on IP matters related to the transaction.
Client Highlights
6.01.26
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to $32.5 Million Series A Financing
On June 1, 2026, Oak Hill Bio, a clinical-stage rare disease therapeutics company, announced the closing of a $32.5 million Series A financing. The round was co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, with participation from KCap Biotechnology Fund. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.
News Articles
6.01.26
Wilson Sonsini Joins Nucleate Leadership Council as Co-Founding Member
On June 1, 2026, Nucleate, a nonprofit organization dedicated to empowering the next generation of biotech leaders, announced the launch of the Nucleate Leadership Council (NLC), a new community of biotech leaders and disruptors committed to supporting the next generation of scientists and entrepreneurs. Wilson Sonsini is proud to join the NLC as a co-founding member.
News Articles
5.21.26
Michael Hostetler Recognized Among Daily Journal’s 2026 Top IP Lawyers
On May 21, 2026, Wilson Sonsini partner Michael Hostetler was recognized in the Daily Journal’s special report "Top Intellectual Property Lawyers 2026," an annual list honoring California's top lawyers specializing in patent litigation, trademark, and copyright. Michael has over 25 years of experience specializing in patent law for life sciences companies, particularly in pharmaceuticals and biotechnology.
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.